Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Other Non-Current Liabilities (2016 - 2020)

Vistagen Therapeutics (VTGN) has disclosed Other Non-Current Liabilities for 9 consecutive years, with $5.9 million as the latest value for Q4 2020.

  • Quarterly Other Non-Current Liabilities rose 26.4% to $5.9 million in Q4 2020 from the year-ago period, while the trailing twelve-month figure was $5.9 million through Dec 2020, up 26.4% year-over-year, with the annual reading at $5.0 million for FY2020, N/A changed from the prior year.
  • Other Non-Current Liabilities hit $5.9 million in Q4 2020 for Vistagen Therapeutics, up from $5.7 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $5.9 million in Q4 2020 to a low of $946000.0 in Q2 2016.
  • Historically, Other Non-Current Liabilities has averaged $3.3 million across 5 years, with a median of $3.0 million in 2018.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 343.51% in 2016 and later dropped 24.49% in 2017.
  • Year by year, Other Non-Current Liabilities stood at $1.3 million in 2016, then skyrocketed by 75.05% to $2.3 million in 2017, then soared by 47.43% to $3.5 million in 2018, then skyrocketed by 35.59% to $4.7 million in 2019, then grew by 26.4% to $5.9 million in 2020.
  • Business Quant data shows Other Non-Current Liabilities for VTGN at $5.9 million in Q4 2020, $5.7 million in Q3 2020, and $5.3 million in Q2 2020.